The strong H1 performance and reaffirmed guidance signal continued operational momentum. The new $50M plasma deal adds a visible revenue stream starting Q4 2026. However, the CFO transition introduces near-term execution risk. Monitor for updates on the CFO search and Q3 results for confirmation of the growth trajectory.
Drugs in focus
KMDA drug pipeline →CYTOGAM
● Neutral Named in this 6-K- Impact
- Phase
- Approved
- Time to market
- Already FDA-approved and commercially marketed
- Next catalyst
- None dated
What to watchCYTOGAM contributes ~12-13% of Kamada's total revenue (~$22.5M in 2024) and is growing 31% YoY, but is not a binary catalyst for the stock. Watch Q2 2026 earnings (~Aug 12, 2026) for CYTOGAM sales trajectory and any updates on the SHIELD study. The stock's primary drivers are Glassia (alpha-1 antitrypsin) and KEDRAB (rabies IG), which represent larger revenue streams.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 12 $6.88entry
- T+1 · 3mo ago +5.52%α +4.83% · $7.26
- T+5 · 3mo ago +14.68%α +15.12% · $7.89
- T+20 · 2mo ago +16.13%α +18.03% · $7.99
- T+60 · 12d ago −0.15%α +4.97% · $6.87
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kamada reported record-high Q2 and H1 2026 results with double-digit revenue and profit growth, driven by strong demand for KEDRAB, VARIZIG, and HEPAGAM. The company affirmed its 2026 annual guidance of $200-205M revenue and $50-53M adjusted EBITDA. A new $50M three-year plasma supply agreement was secured, and the company announced the planned transition of its CFO, Chaime Orlev, effective end of 2026. The strong operational performance is partially offset by a slight gross margin decline and the CFO departure introduces a leadership transition risk.
Key Facts
- Record-high H1 2026 revenues of $100.2M, up 13% YoY
- Record-high H1 2026 adjusted EBITDA of $25.7M (26% margin), up 14% YoY
- Q2 2026 revenues of $54.9M, up 23% YoY; Q2 net income of $9.3M, up 26% YoY
- Affirmed 2026 annual guidance: $200-205M revenue and $50-53M adjusted EBITDA
- Secured a 3-year, ~$50M plasma supply agreement with a leading biopharma company
- CFO Chaime Orlev to transition out by Dec 31, 2026; successor search underway
- Cash from operations in H1 2026 was $17.8M, up from $7.5M in H1 2025
- Gross margin declined to 42% in H1 2026 from 45% in H1 2025
Financial Impact
H1 2026 revenue $100.2M (+13% YoY), net income $13.4M (+18% YoY), adjusted EBITDA $25.7M (+14% YoY). Cash and short-term investments $70.1M as of June 30, 2026.
Risk Factors
- CFO transition could cause temporary operational disruption
- Gross margin compression (42% vs 45%) warrants monitoring
- Geopolitical risks from Middle East operations and potential tariff impacts
- Dependence on a few key products (KEDRAB, GLASSIA, CYTOGAM) for revenue concentration
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-088030 |
| Document: ea029970701ex99-1.htm | 0001213900-26-088030 |
| Document: ea0299707-6k_kamada.htm | 0001213900-26-088030 |
| Document: ea029970701ex99-2.htm | 0001213900-26-088030 |
| Document: ea029970701ex99-4.htm | 0001213900-26-088030 |
| Document: 0001213900-26-088030-index-headers.html | 0001213900-26-088030 |
| Document: 0001213900-26-088030-index.html | 0001213900-26-088030 |
| Document: 0001213900-26-088030.txt | 0001213900-26-088030 |
Track record
25 reports on KMDA
7 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +12.08% at T+60 after the Jun 1, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 No price data
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
- Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
- Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
- Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
- Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers